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After entry of the human immunodeficiency virus type 1 (HIV-1) into T cells and the subsequent synthesis of viral products, viral proteins
and RNA must somehow find each other in the host cells and assemble on the plasma membrane to form the budding viral particle. In this
general review of HIV-1 assembly, we present a brief overview of the HIV life cycle and then discuss assembly of the HIV Gag polyprotein
on RNA and membrane substrates from a biochemical perspective. The role of the domains of Gag in targeting to the plasma membrane and
the role of the cellular host protein cyclophilin are also reviewed.D 2003 Elsevier B.V. All rights reserved.Keywords: HIV-1; Gag; Viral assembly1. Introduction
The human immunodeficiency virus (HIV) is the caus-
ative agent of acquired immune deficiency syndrome
(AIDS). There are two subtypes of HIV, HIV-1 and HIV-2.
Currently, more than 40 million people worldwide are
infected with HIV-1. HIV is a member of the retrovirus
family (for general background see Refs. [1,2]). These
viruses possess a single-stranded RNA genome that is
converted to double-stranded DNA shortly after infection
of susceptible host cells. The DNA copy of the genome is
transported into the nucleus where it is integrated into
chromosomal DNA and replicated by host factors. In the
case of HIV, the late stages of viral assembly occur on the
inner leaflet of the plasma membrane. Virus release occurs
by budding, permitting the virus to obtain a host-derived
lipid envelope. The compositions of the viral envelope and
the plasma membrane are not equivalent, suggesting that
virus assembly may occur in nonrandom subdomains of
cellular membranes.
The HIV-1 genome is comprised of nine genes (Fig. 1A).
Six are unique to the HIV virus; three are common to other
retroviruses. The common major genetic domains are 5V-0005-2736/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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Although all nine viral genes are essential for assembly of
an infectious particle, the gag gene alone can direct the
synthesis, transport to the plasma membrane, and assembly
of the structural precursor polyprotein Gag, resulting in
formation of particles that are morphologically indistin-
guishable in the electron microscope from immature (non-
infectious) virus. The pol gene encodes the enzymatic
proteins protease (PR), reverse transcriptase (RT), and
integrase (IN). Expression of pol with gag results in PR-
catalyzed proteolytic maturation of Gag and formation of
particles that are morphologically indistinguishable in the
electron microscope from authentic, mature, infectious virus
(Fig. 1B). The env gene yields a precursor for the envelope
glycoproteins gp120 and gp41. The surface (SU) glycopro-
tein gp120 determines cell tropism by attaching to CD4
receptors and specific co-receptors (members of diverse
chemokine receptor molecules) on the surface of cells of
lymphatic lineage. This action brings the viral and cellular
membrane in sufficient proximity to promote lipid fusion
mediated by the transmembrane (TM) glycoprotein gp41.
Gene expression is achieved by three distinct mechanisms.
Gag is translated directly from viral RNA. Env is encoded in
a spliced mRNA. Pol is expressed as a Gag–Pol fusion
product made by infrequent ribosomal frameshifting. This
frameshifting is a subtle form of regulation that ensures
overproduction of the structural gag gene products relative
to the enzymatic pol gene proteins.
Fig. 1. (A) Organization of the HIV-1 proviral genome. (B) Organization of the HIV-1 mature viral particle.
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reflect similar mechanisms of assembly. Motifs that direct
membrane binding, particle release, and high particle
density are functionally interchangeable in the Gag struc-
tural precursor polyprotein. In HIV-1, each virion contains
f 2000 copies of Gag. The Gag polyprotein, which is by
itself sufficient for formation of immature particles, forms
a spherical shell that looks similar for all retroviruses. The
structural proteins that comprise mature infectious virus
particles, matrix (MA), capsid (CA), spacer p2, nucleo-
capsid (NC), and spacer p1 and p6, originate from domains
in Gag (Fig. 1B). The outermost shell underlying a lipid
bilayer, derived from the plasma membrane during bud-
ding, is composed of MA. There is an inner core com-
prised of a shell assembled from the CA protein and inside
this core is a ribonucleoprotein containing NC complexed
to the diploid genomic RNA and the replicative enzymes.
The Gag–Pol polyprotein contains all of the domains in
Gag except for p6 in addition to the enzymes PR, RT, and
IN, as noted above. Concomitant with, or following therelease from infected cells, all retroviruses undergo mor-
phological rearrangements associated with cleavage by
viral PR of the precursor polyproteins into mature prod-
ucts. Activation of viral PR and proteolytic processing of
the precursor proteins are essential steps in formation of
infectious virus and convert the spherical immature particle
to particles containing a characteristic conical-shaped cap-
sid. In the mature particle, the host-derived membrane
envelope is studded with the surface glycoprotein gp120
(SU) and the TM glycoprotein p41. SU and TM are also
formed from precursor proteins (gp160). Proteolytic pro-
cessing of the Env precursor into mature proteins occurs
by cellular proteases.
The life cycle of HIV-1 is shown in Fig. 2 where the
virus first enters the host cell and disassembles. RNA is
then transcribed to DNA and associates with a pre-integra-
tion complex which enters the nucleus. The newly synthe-
sized viral proteins are then trafficked to the plasma
membrane where they assemble and bud from the cell to
give the mature form of the virus. Since the Gag poly-
Fig. 2. Life cycle of HIV-1.
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the role of the individual Gag domains in controlling HIV-1
assembly.2. Role of the individual Gag domains in viral assembly
2.1. Structure and function of the matrix protein (MA)
2.1.1. Conformation and oligomerization of MA
The MA domain of Gag is the region that forms the final
contacts with the plasma membrane of the host cell and
interacts with gp120 [3]. In virions, the MA domain is
visualized as a thin membrane-bound layer by cryoelectron
microscopy [4]. Structural analysis of recombinant MA
shows that the membrane-binding face is comprised of a
cluster of basic residues in the N- and C-terminal region that
are brought into proximity by the three-dimensional fold ofthe protein [5] (Fig. 2). Genetic studies demonstrate that the
regions responsible for membrane binding are located on the
N-terminal region of MA which encompasses a cluster of
basic residues and a myristyl group [6]. The protein crys-
tallizes as a trimer with four helixes arranged in a circular
pattern and one helix extending outward from the other four
(Fig. 3). These helices are then capped off by a three-
stranded mixed E-sheet. The membrane-binding face of
each subunit is tilted f 30j from the trimer interface
encompassing helix 2, so it is unlikely that the protein
would remain an oligomer with the same subunit contacts
after membrane binding. Supporting this idea are fluores-
cence studies that have shown that even under conditions
where MA is a trimer in solution, binding to model
membranes results in complete dissociation of the oligomer
[7]. Based on these studies and the observation that Gag can
still form infectious particles if all of the MA domain was
deleted expect for the myristoylation signal, it appears that
Fig. 3. (A) Organization of MAwhere NES and NLS refer to nuclear export and nuclear localization signals, respectively, and H1–5 refer to helices 1–5. (B)
Ribbon diagram of the matrix protein.
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observations do not argue against the idea that the MA
domain may form trimers in the Gag–RNA complex that
precedes membrane binding (see below). Mutations in the
N-terminal region typically result in altered membrane
binding and, in some cases, assembly and release events
are affected [9]. The conclusion from these and other studies
is that residues in the N-terminal domain of MA may affect
assembly directly by fine-tuning Gag–Gag contacts made
during assembly, or indirectly by affecting the structure of
upstream domains.
2.1.2. Interaction of matrix with lipid membranes
The membrane binding properties of MA have been
characterized both in vitro and in vivo [6,10,11]. Like
Gag, purified MA binds most strongly to negatively charged
vesicles as would be expected for a protein that contains ahighly positively charged face. Even though other Gag
domains may participate in membrane association [10],
the MA domain of Gag, including its myristoylation signal,
appears to be primarily responsible for plasma membrane
targeting, since alterations in MA can result in loss of
membrane association or the mislocalization of Gag to other
cellular compartments [12,13]. A schematic of the MA
sequence and structure is presented in Fig. 3.
Recently, many investigators have focused on the target-
ing of MA to lipid rafts in cells (see Ref. [14]). The
description of lipid rafts was based on studies of the
composition of the pellet fraction that remains after treat-
ment of cells with a mild detergent, such as Triton X-100,
(for review see Ref. [15]). These pellets contain a high
composition of cholesterol and sphingomylein. Pellets of
similar cholesterol and sphinglomylein ratios also form after
detergent treatment in vitro using model membranes of
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properties. Phase diagrams of these lipid mixtures showed
that if lipids that have at least one saturated acyl chain are
mixed with at least 33% cholesterol, then cholesterol will
aggregate at temperatures above the phase transition of the
lipid, usually below 4 jC. If a lipid with saturated chains
was incorporated into this system, then the saturated chains
could complex with cholesterol to form a ‘liquid-ordered’
phase which is characterized by high lipid mobility (see Ref.
[15]). The term lipid raft was used to indicate that domains
of lipids in the liquid-ordered phase coexist or ‘float’ in the
lipids in the more fluid, liquid-disordered phase. Note that
lipid rafts differ from caveolae which are ordered domains
that contain high amounts of the protein caveolin.
Since the detection of lipid rafts in cells involves disrup-
tion and fractionation of the plasma membrane, then it is
difficult to determine whether the protein aggregates that
also pellet after cell disruption are associated with rafts [16].
Many studies of this type have implicated Gag-raft associ-
ation (e.g. Refs. [17–21]). However, one could argue that
the main components of rafts are uncharged and, since MA
prefers negatively charged surfaces (see below), it is likely
that the MA domain of Gag would prefer to be localized
outside of rafts.
It has been well-established that GPI-anchored proteins
target exclusively to rafts and these can be used as markers
to define these regions in membranes as can other commer-
cially available lipid fluorescent probes. Fluorescence mi-
croscopy studies using these markers show that HIV-1 Gag
is targeted to raft domains, supporting studies using sepa-
ration techniques [22]. It is noteworthy that one factor that
has been shown to be responsible for raft localization in
other protein systems is the presence of two saturated acyl
chains, such as myristoyl and palmitoyl. Studies using
model systems indicate that the MA membrane targeting
signal, i.e. the basic residues and myristylation, will not
result in raft-targeting [23] and thus for HIV-1 to localize to
rafts, some other factor such as interaction of MA and
envelope proteins [24], or fusion from endosomal mem-
branes, must be responsible.
As expected from its sequence, the positive lobe of MA
results in a strong attraction to membranes with negatively
charged lipids and in vitro MA shows much weaker affinity
towards electrically neutral membranes [25]. Since the inner
leaflet of the plasma membrane is enriched in acidic phos-
pholipids, it is possible that these negatively charged lipids
could localize proteins with basic domains to the cytoplas-
mic face of the membrane. However, other cellular regions
may contain anionic regions and so the precise roles of both
the positive residues and myristoylation are still unclear.
Based on in vitro measurements of the membrane energy of
unmyristoylated Gag to model membranes the myristoyl
moiety should only contribute f 1% of additional the
binding energy [25,26]. Gag mutants lacking the myristoy-
lation signal localize to other cellular membranes besides the
plasma membrane and so the myristoyl group is thought toserve some targeting function [12,13]. Other myristoylated
proteins are found in other cellular compartments and so it is
unlikely that this signal serves solely as a plasma membrane
targeting signal. It is also noteworthy that other closely
related retroviruses do not use this signal and must use other
unidentified plasma membrane targeting signals (e.g. Ref.
[27]). Since some population of MA must interact with
membranes in transient fashion (see below), it has been
suggested that while in the context of Gag, the myristoyl
group of MA is freely available to directly interact with the
lipid bilayer and promote membrane binding. This model,
termed the ‘myristoyl-switch model’, states that while the
myristoyl group is exposed in the context of Gag, upon Gag
maturation, MA refolds in such a way as to sequester the
myristoylate in the protein matrix and thereby decrease its
membrane affinity (see Refs. [28–30]). Indirect support for
this model comes from numerous in vivo studies (e.g. Refs.
[29,31]). At this point, it is unclear whether the myristoyl
group is exposed in the context of Gag and can contribute
directly to the membrane binding of Gag.
More insight into the possible role of myristoylation
comes from studies in transiently transfected COS cells
which have shown that myristoylation results in the forma-
tion of higher order Gag proteins in the cytosol that
presumably are primed to target the plasma membrane
[11]. While myristoylation may promote oligomerization
of the Gag precursor by providing a hydrophobic patch to
stabilize protein–protein associations, some proteolytic and
antigenic sites differ when the myristylation group is at-
tached, indicating that interaction of the myristoyl group
with the protein core may result in alterations in the tertiary
structure as well [32].
2.1.3. Role of matrix in virus assembly
As mentioned, in the context of Gag–Gag protein
associations, it is unlikely that trimer formation of MA
drives assembly per se or that the MA domain is required.
However, mutations that prevent trimer formation in solu-
tion adversely affect Gag assembly [26,27]. And in pro-
cessed form, NMR studies show that both MA and MA–CA
form trimers in solution while isolated CA is monomeric
under similar conditions [33].
The MA domain controls membrane binding and this
membrane association, rather than its protein–protein con-
tacts, is expected to be the primary role of MA in assembly.
In vitro studies using model membranes and purified pro-
teins and also fractionation studies in COS cells have shown
that the membrane binding affinity of MA is weaker than that
of the whole Gag protein [6,10,28]. Mutations in the N- or C-
terminal domains of MA usually result in impaired binding
in cells and, often, second mutations in other globular
regions of MA can reverse this effect [34], supporting the
idea that specific MA contacts are made during assembly. In
model membranes, both mature CA and NC can interact with
membranes [10], but it is unlikely that they contribute to
membrane binding in vivo since these domains serve to
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Although this leaves MA as the primary membrane binding
motif, in COS cell studies where the MA region was deleted
and only the myristoyl signal remained [35,36], and studies
where the MA region was replaced by a different viral
protein, membrane binding and targeting of Gag were not
affected, leading to the idea that trafficking of Gag in vivo is
more complex than being driven by simply biophysical
interactions between Gag and the plasma membrane (e.g.
Ref. [37]). It is also important to note that in vitro assembly
of Gag can occur in the absence of membranes [38,39].
2.1.4. Role of MA in non-assembly events
Besides membrane binding, MA may play other roles in
the HIV-1 life cycle. MA has been implicated in release
from the host cell mediated by the viral protein Vpu [40].
Also, MA appears to aid in the transport of HIV components
into the nucleus. During the initial stages of virus infection,
a small population of MA dissociates from the membrane,
exposing a nuclear localization signal, and becomes incor-
porated into the preintegration complex [41,42]. Interesting-
ly, one region of this nuclear localization signal lies in the
highly basic region of MA that is involved in membrane
binding and thus membrane binding must be somehow
weakened to allow for MA dissociation (Fig. 3). While
certain factors are known to weaken MA–membrane inter-
actions, such as cleavage of the MA domain from Gag and
dissociation of the MA trimers to monomers, most likely,
other signals such as phosphorylation [43] or strong inter-
action with the other preintegration proteins occur. Note that
another viral protein, Vpr, also contains a seemingly redun-
dant nuclear localization signal.
MA also contains a signal to be exported out of the
nucleus [44]. Nuclear export of MA is mediated by a central
component in the protein export pathway, Crmp1p. Thus,
MA dissociates from the membrane in the early stages of
infection and incorporates into the preintegration complex
which then enters the nucleus. During this time, the nuclear
export signal must somehow be masked either by occlusion
from components in the preintegration complex or by a
modification such as phosphorylation. The nuclear export
signal counteracts the nuclear localization signal to keep
Gag in the cytoplasm and out of the nucleus. Since MA
plays at least two critical roles in the HIV life cycle, it is not
surprising that mutations in this region affect infectivity and
viral transmission.
2.2. Structure and function of the capsid domain
2.2.1. Structure and assembly of capsid proteins
Sequentially located in the center of the Gag is the CA
domain whose role in the viral life cycle is less understood
(Fig. 1). Evidence exists for its essential role in particle
assembly [36,37] and in vitro mature capsid alone has the
capacity to assemble into particles [25]. However, the
manner in which CA is organized in virus particles is notclear but several studies suggest regions of protein–protein
interactions in the C-terminal domain or hexamerization in
the N-terminal region [45–50]. Morphologically, mature
CA forms the distinctive conical core of the virus that
encapsulates the viral RNA–protein complex. Virions with
abnormal core structures are defective in initiation of reverse
transcription and exhibit reduced infectivity [51]. Thus, CA
provides structural stability to the virion and also plays a
key role in forming the protein–protein contacts required
for productive assembly.
Sequentially, CA can be divided into two domains, an N-
terminal domain (NTD) and a C-terminal domain (CTD)
(Fig. 4). The structure of these separate domains as well as
the whole protein has been solved [49,52,53]. In Fig. 5 we
show the structure of capsid as solved using an Fab antibody
to promote structural integrity and crystallization [54]. The
N-terminal domain consists of five long helices forming a
stable coiled-coil structure, two short ones, two E-hairpins,
and a Pro-rich loop. Although mutations in the N-terminal
domain adversely affect core formation, the first 56 residues
can be deleted without adversely affecting particle assembly.
Deletions in the Pro-rich region give wild-type morphology
but a loss in infectivity, which is thought to be due to loss of
the incorporation of the host protein cyclophilin into the
virions (see below).
Upon cleavage of CA from MA, the N terminus is
thought to refold to form a new E-hairpin helix stabilized
by a buried salt bridge between Pro1 of CA and the carboxyl
side chain of Asp51 [55]. N-terminal extensions ranging
from a few residues to the entire MA domain on CA prevent
the conversion from spherical to tubular structures while
mutations in the spacer behind the C-terminal domain of CA
affect aggregation but do not give regular tubular structures
[38,56]. It is this change upon MA cleavage which is
thought to be associated with the dramatic transformation
to conical structures. Spherical, immature-like and tubular,
mature-like CA assemblages can form from mature CA or
CA-p2-NC in vitro, and a switch from tubular to spherical
forms can be induced by changing the pH from 7.0 to 6.8
[57,58]. It is unlikely that this small change in pH alters the
protonation state of the N terminus and more likely that
other CA residues are involved. Nevertheless, the proximity
of this switch to physiological pH values indicates that the
local electronic environment in the virion may be critical in
the maturation process.
The C-terminal half of CA contains four conserved
helices and a highly conserved sequence among retroviruses
known as the major homology region (MHR; 285–304 in
HIV-1; see Fig. 4). This region is conserved throughout the
retrovirus group [59] and thus offers a novel and stable target
for viral vaccines. The role of the MHR sequence has been
investigated using mutagenesis and biophysical strategies.
Various mutations within the MHR block viral replication at
different and distinct stages, such as assembly, maturation, or
target cell infection in vivo, indicating that the MHR may
play a role in Gag interactions with viral protein, the host
Fig. 4. Linear representation of the HIV Gag proteins CA (A), NC (B) and p6 (C).
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plays a role in membrane binding comes from biophysical
studies showing that purified MHR-deleted Gag has a
reduced binding affinity to model membranes as compared
to wild-type Gag [53,61,62]. Indeed, deletion of the MHR
results in abnormal Gag processing and we have shown that
MHR-deleted Gag no longer has the ability to assemble on
membrane or RNA substrates in vivo or in vitro, arguing that
the critical contacts needed for Gag oligomerization reside in
this region [63]. These results suggest that the MHR deter-
mines the Gag conformation required for productive pro-
tein–protein and protein–membrane interactions during
assembly. Extending these studies to the assembly of wild-
type Gag, RNA may act to seed the formation of Gag
oligomers and the contacts in the CA domain may stabilize
the aggregates.
2.2.2. The role of the host cell protein cyclophilin in the HIV
life cycle
There are several host proteins that become incorporated
into HIV virions but only one of these, cyclophilin A, has
been shown to enhance viral infectivity[64–68]. Cyclo-
philin A (CypA) is a cytosolic protein that catalyzes the
cis–trans isomerization of proline residues and is the target
of the immunosuppressive drug cyclosporin [69]. Cyclo-
philin A is recruited into the virions through interactions
with a proline-rich stretch in the N-terminal region of thecapsid domain [70]. Only the retroviruses HIV and chim-
panzee-specific SIV require cyclophilin A, and cyclophilin
A dependency can be transferred to other viruses by
transferring the cyclophilin A binding site. The Gag binding
site for cyclophilin A, Gly89–Pro90 in capsid (Fig. 4), exists
in both the cis and trans forms and recent studies show that
cyclophilin does catalyze Gly89–Pro90 isomerization of
capsid, suggesting a role for cyclophilin in maturation or
disassembly [50,71]. The loop containing Pro90 in the
capsid domain binds directly to hydrophobic binding pocket
of cyclophilin [70] although other CA association sites may
exist [72]. Conditions that disrupt cyclophilin A–CA asso-
ciation, such as the addition of cyclosporin, mutation of the
association site, or depletion of the host cells cyclophilin A,
lead to less infectious viruses that show reduced replication
[73]. This loss in infectivity suggests that cyclophilin A
plays some vital role in the virus’s life cycle. Arguing
against a role of cyclophilin A in late events is the observa-
tion that disruption of Gag–cyclophilin interaction still
allows for assembly and budding to give particles that have
the proper number of copies of Gag. The ratio of 10 copies of
CA to 1 copy of cyclophilin in virions is supported by
fluorescence binding studies, showing that cyclophilin will
only bind to an aggregated form of immature CA and not a
dissociated one [74]. This result suggests that the primary
binding site for cyclophilin may lie across several subunits in
a CA oligomer.
Fig. 5. Structure of capsid from Ref. [54]. This structure is of a protein with
an amino-terminal extension containing His6 tag. The amino-terminal
extension implies that this structure to some extent simulates capsid in the
context of Gag. The green region represents the MHR. NTD is the amino
terminal domain and CTD is the carboxy terminal domain.
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philin A does not affect the oligomerization or dissociation
of a form of CA that mimics immature conformation [74].
Since cyclophilin A does not affect the later assembly stages
of the virus, it may assist in disassembly or uncoating of CA
from the viral genome in the early stages of infection [64–
66,75]. Indeed, cyclophilin binds differently to Gag and
mature capsid, supporting the suggested role in post-assem-
bly events [50]. It appears that the proline isomerase activity
of cyclophilin is important for replication, and thus the
isomerase activity of cyclophilin may be needed to act on
some host protein for proper uncoating or, alternately, the
cyclophilin protein may promote uncoating in a nonenzy-
matic manner.
It has also been observed that inhibitors of cyclophilin
reduce the efficiency of viral attachment to target cells
[76,77]. There are cyclophilin B receptors on the surface
of T cells, and it is possible that cyclophilin A moves to the
exterior surface of the virion and binds to this receptor
aiding in docking and entry. However, our laboratory found
that both cyclophilin A, capsid, and the complex are
incapable of moving across or fusing to a model membrane
surface, and so how this process would work is unclear (M.
BonHomme, C. Carter and S. Scarlata, unpublished results).
We have found that the binding affinity of cyclophilin A to
capsid decreases dramatically as CA matures which could
allow cyclophilin to dissociate from its binding site in the
mature virion and move to other locations in the virus.While cyclophilin has been implicated in promoting
uncoating of CA, phosphorylation may also play a role
[78]. CA has been shown to have three phosphorylation
sites in vitro and two cellular kinases have been found in
virions [79]. One of these kinases, MAPK ERK2, does not
phosphorylate CA in vitro and so the second, unidentified
kinase may be responsible.
2.3. Role of the nucleocapsid domain in the assembly of
HIV particles
2.3.1. The importance of RNA binding to NC in Gag
oligomerization
The NC domain of Gag is a highly basic region whose
role is to encapsulate and protect viral RNA. Two copies of
RNA are contained in each particle and the NC domain
binds to these RNA through its zinc fingers (Fig. 4). The
two fingers have been shown to be the minimal element
needed for RNA binding. Proper encapsidation of the HIV
genome has been found to involve an f 110-nucleotide
segment known as the Psi-site, which contains four stem
loops which are required for genome packing. Two of these
stem loops bind to NC while one is thought to stabilize the
structure of the site [80].
It is RNA binding that aids in localizing and concentrat-
ing Gag monomers to promote Gag assembly. While Gag
does not show a strong binding preference for RNA over
membranes in vitro, COS cell studies indicate that RNA
binding of Gag precedes membrane binding, most likely due
to a closer proximity between the two during assembly and
in vitro studies support this pathway [63]. It is reasonable to
assume that the localization of Gag monomers on RNA
promotes Gag–Gag interactions between the CA and MA
domains. The role of RNA in assembly is so vital that HIV
will recruit other cellular RNAs if viral RNA is not available
[81]. Upon Gag processing, NC promotes the refolding of
genomic RNA to a thermostable dimer [82,83].
The region of nucleocapsid that binds RNA is the
conserved I or interaction domain containing the zinc
fingers [84,85]. This domain, which was first identified in
RSV, is present in two copies in HIV and is required to form
particles of proper density [86,87]. Interestingly, the zinc
fingers are not necessary for I domain function and a string
of basic residues can function as an I domain in RSV.
However, charge alone cannot completely mimic I domain
function and the observation that some of these I mutants
can be rescued by subsequent mutagenesis leads to the
simple model that the two I domains work in conjunction
to correctly package RNA [88].
2.3.2. Do inositol phosphates participate in assembly?
In addition to membranes and RNA, there is good
evidence that inositol phosophates may play a role in HIV
assembly [89]. Inositol phosphates can be generated in the
cell by various signaling proteins as well as simple house-
keeping proteins. Inositol phosphates are rapidly generated
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cells is very dynamic and difficult to quantify. However, it is
not surprising that the high concentration of basic residues
in the MA and NC domains would bind these small, anionic
molecules and this binding may aid in the condensation of
Gag molecules during assembly.
2.3.3. Binding of NC to VPR
Another important function of NC in terms of assembly
is to incorporate cellular Vpr into virions along with the p6
domain [46,90,91]. As mentioned above, Vpr participates
with MA in the preintegration complex and can induce cell
cycle arrest in the G2 phase [92]. Vpr seems to associate to
Gag through its C-terminal 16 residues and possibly the
zinc fingers of NC [93]. It is possible that the Vpr–NC
complex may work to interact with proteins involved in cell
division.
2.4. Role of p6 in the late stages of the HIV life cycle
This small segment is at the sequential end of Gag and
contains the late (L) domain which is required for the
pinching off of the newly assembled virion from the host
membrane (Fig. 4).
Within the p6 region of HIV-1 is a proline-rich motif
PTAP(P), which appears to play critical roles in exocytosis
of the assembled particle [94]. Our laboratory discovered
that this region directly interacts with Tsg101, which is a
host component of the cellular endocytosis machinery [95],
and two other groups have found that budding and matura-
tion is dependent on tsg101 gene expression [96–98].
Tsg101 is an orthologue of the yeast vacuolar protein sorting
protein 23 (Vps23) and an inactive homologue of Ub
conjugating (E2) enzymes (see Ref. [99]). E2 enzymes
transfer Ub to E3 enzymes. The PTAP(P) motif in HIV-1
Gag recruits a multi-component complex containing pro-
teins involved in the trafficking machinery. This was ele-
gantly demonstrated by Garrus et al. [96], who used small,
interfering RNA (siRNA) to deplete cells of Tsg101 and
block viral budding from the membrane. These investigators
then linked the requirement for Tsg101 to the endosomal
trafficking machinery by showing that dominant-negative
mutants of Vps4, an ATPase required for intracellular
trafficking of Tsg101, prevents virus release in an L-do-
main-dependent manner.
Protein trafficking through ubiquitin has been explored in
other systems (see Ref. [100]). Ubiquitin (Ub)-dependent
proteolysis is an important regulatory mechanism involved
in diverse cellular functions such as cell cycle control, signal
transduction, and regulation of membrane channels (see Ref.
[100]). In the ubiquitinylation pathway, the Ub activation
enzyme (E1) activates Ub by hydrolyzing ATP to form a
high energy bond with Ub. Ub is then transferred to a Ub
conjugation enzyme (E2, UbC) by formation of a thioester
linkage between the C-terminal Gly of Ub and the SH group
of the active site Cys in E2. Interactions between E2 andsubstrate proteins result in transfer of Ub to the epsilon-
amino groups of lysine side chains on the substrate by
catalyzing the formation of an isopeptide bond. In some
cases, this process is mediated by a Ub protein ligase (E3).
The E3 enzyme also catalyzes transfer of additional Ub
molecules to form a polyubiquitin chain. It is believed that a
single E1 transfers Ub tof 30 human E2 enzymes and that
each E2 transfers to several E3s. The E3s can be substrate-
specific or can recognize several substrates via similar but
not identical motifs. Certain substrates can be targeted by
several E3s, probably through distinct recognition motifs.
Tsg101 has a functional link to Ub and Ub has been found
either linked to lysine residues in p6 and/or free in purified
virus particles of HIV-1 [79], suggesting that Ub plays a role
in Gag trafficking. Additionally, residues in the NC region
may also assist in this process [102]. Since at least four Ub
are needed for efficient recognition for the proteosome [103]
then polyUb Gag would be designed for degradation. These
recent discoveries of the ability of HIV-1 Gag to exploit the
cellular endocytotic machinery are expected to be explored
in the upcoming years (see Refs. [101,104–107]).3. Working model of HIV assembly
From the studies describe above, we can propose the
following model for HIV-1 Gag assembly. Gag is first
synthesized on free polysomes in the cytosol. It is probable
that Gag then binds to intracellular vesicles entering the
endosomal trafficking system. During or shortly after this
time, Gag is exposed to newly synthesized viral RNA.
While this interaction may occur in the cytosol, there is a
finite probability that it occurs in the nucleus and whether
the Gag–RNA complex exits through the nuclear export
signal on MA is not clear. Binding to RNA through the I
domain on NC localizes Gag onto the RNA strand, thereby
promoting Gag–Gag association. This oligomerization and
subsequent condensation of Gag occur through several
contact points leaving Gag vulnerable to mutations that
disrupt efficient protein–protein interactions. Gag oligomer-
ization most likely occurs concurrently with RNA conden-
sation and it is possible that highly charged free inositiol
phosphosphates may aid in this condensation process. When
Gag enters the endosomal trafficking machinery, the MA
region becomes bound to endosomal lipids. The final
delivery of Gag to the plasma membrane most likely
involves the fusion of the endosomal membrane with the
plasma membrane. This process would negate the state of
Gag oligomerization before lipid binding, supporting cell-
based studies indicating that tight Gag complexes are not
required for complexation [108] even though in vitro studies
show a weaker binding of the complex as opposed to the
monomer [10]. The presence of RNA bound to the zinc
fingers of NC may assist in appropriately positioning Gag in
the correct orientation to the membrane surface thereby
promoting interactions between the CA domain although,
S. Scarlata, C. Carter / Biochimica et Biophysica Acta 1614 (2003) 62–72 71since assembly will occur if the zinc fingers are deleted, this
interaction is not required [109]. The N-terminal region of
MA will contact with the membrane surface, and also
contact with envelope proteins that are localized in lipid
rafts which have most likely also undergone oligomerization
[110]. As more Gag–RNA is delivered to the membrane,
the particle buds outward from the cell and this budding
maybe aided by the lipid composition of the underlying
surface. The final interaction between p6 and some exocy-
totic machinery allows viral release in an energy-dependent
fashion [111]. Shortly after or concurrently, maturation is
triggered by some unknown process to yield infectious
particles.4. Concluding remarks
Even with the wealth of information about the assembly
of HIV-1 in host cells, many questions as to how the various
viral components find their way to the plasma membrane
and interact to form productive complexes remain. While
much can be gathered from numerous mutagenesis studies
of the Gag protein and its individual domains, the challenge
now is finding the specific host components, whether in the
trafficking machinery or in the nucleus, that these domains
must interact with to form productive complexes that can
mature into infectious particles.Acknowledgements
The authors are grateful to the generous support of the
NIH GM58271 and to Marjorie BonHomme and Paxton
Provitera for critically reading the manuscript and providing
Fig. 5. The authors are grateful to Lynn VerPlank and Eva
Guttwein for Figs. 1–4. The authors would also like to
acknowledge the many background citations that were too
numerous to specifically cite in the text, but nevertheless
contributed to progress in this field.References
[1] J.M. Coffin, S.H. Hughes, H.E. Varmus, Retroviruses, Cold Spring
Harbor Laboratory Press, Woodbury, NY, 1997.
[2] A.D. Frankel, J.A. Young, Ann. Rev. Biochem. 67 (1998) 1–25.
[3] H.R. Gelderbloom, AIDS 5 (1991) 617–638.
[4] T. Wilk, I. Gross, B.E. Gowen, T. Ruttne, F. de Haas, R. Welker,
H.G. Krausslich, P. Boulanger, S.D. Fuller, J. Virol. 75 (2001)
759–771.
[5] C. Hill, D. Worthylake, D.P. Bancroft, A.M. Christensen, W.I. Sund-
quist, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3099–3104.
[6] W. Zhou, L. Parent, J. Wills, M. Resh, J. Virol. 68 (1994)
2556–2569.
[7] S. Scarlata, L.S. Ehrlich, C.A. Carter, J. Mol. Biol. 277 (1998)
161–169.
[8] C.-T. Wang, Y.-C. Chou, C.-C. Chaing, J. Virol. 74 (2000)
3418–3422.[9] E.O. Freed, J.M. Orenstein, A.J. Buckler-White, M.A. Martin,
J. Virol. 68 (1994) 5311–5320.
[10] L. Ehrlich, S. Fong, S. Scarlata, G. Zybarth, C. Carter, Biochemistry
35 (1996) 3933–3943.
[11] L. Hermida-Matsumoto, M. Resh, J. Virol. 74 (2000) 8670.
[12] M. Bryant, L. Ratner, Proc. Natl. Acad. Sci. U. S. A. 87 (1990)
523–527.
[13] P. Spearman, J.J. Wang, N.V. Heyden, L. Ratner, J. Virol. 68 (1994)
3232–3242.
[14] S. Campbell, S.M. Crowe, J. Mak, J. Clin. Virol. 22 (2001)
217–227.
[15] D.A. Brown, E. London, Annu. Rev. Cell Dev. Biol. 14 (1998)
111–136.
[16] L. Ding, A. Derdowski, J.J. Wang, P. Spearman, J. Virol. 77 (2003)
1916–1926.
[17] I. Russo, M. Mixon, B. Chen, P.S. Kim, Proc. Natl. Acad. Sci.
U. S. A. 97 (2000) 13523–13535.
[18] Y.H. Zheng, A. Plemenitas, T. Linnenmann, O.T. Fackler, P.M. Pe-
terlin, Curr. Biol. 11 (2001) 875–879.
[19] K. Holm, K. Weclewicz, R. Hewson, M. Suomalainn, J. Virol. 77
(2003) 4805–4817.
[20] A. Ono, E.O. Freed, Proc. Natl. Acad. Sci. U. S. A. 98 (2001)
13925–13930.
[21] O. Linwasser, M. Resch, J. Virol. 75 (2001) 7513–7524.
[22] D. Nguyen, J. Hildreth, J. Virol. 74 (2000) 3264–3272.
[23] J.B. McCabe, L.G. Berthiaume, Mol. Biol. Cell 12 (2001)
3601–3617.
[24] Y.H. Zheng, A. Plemenitas, T. Linnenmann, O.T. Fackler, B.M.
Peterlin, Curr. Biol. 11 (2001) 875–879.
[25] L.S. Ehrlich, B. Agresta, C.A. Carter, J. Virol. 66 (1992)
4874–4883.
[26] R. Peitzch, S. McLaughlin, Biochemistry 32 (1993) 10436–10443.
[27] P. Provitera, F. Bouamr, D. Murray, C. Carter, S. Scarlata, J. Mol.
Biol. 296 (2000) 887–898.
[28] W. Zhou, M.D. Resh, J. Virol. 70 (1996) 8540–8548.
[29] P. Spearman, R. Horton, L. Ratner, I. Kuli-Zade, J. Virol. 71 (1997)
6582–6592.
[30] L. Hermida-Matsumoto, M.D. Resh, J. Virol. 73 (1997) 1902–1908.
[31] A. Ono, E.O. Freed, J. Virol. 73 (1999) 4136–4144.
[32] F. Bouamr, S. Scarlata, C. Carter, Biochemistry 42 (2003)
6408–6417.
[33] Y. Morikawa, W.-H. Zhang, D.J. Hockley, M.V. Nermut, I.M. Jones,
J. Virol. 72 (1998) 7659–7663.
[34] R. Kiernan, A. Ono, E.O. Freed, J. Virol. 73 (1999) 4728–4737.
[35] P.P. Lee, M.L. Linial, J. Virol. 68 (1994) 6644–6654.
[36] C.-T. Wang, Y. Zhang, J. McDermott, E. Barklis, J. Virol. 67 (1993)
7067–7076.
[37] M.A. Accola, B. Strack, H.G. Gottlinger, J. Virol. 74 (2000)
5395–5402.
[38] I. Gross, H. Hohenberg, C. Huckhagel, H.-G. Krausslich, J. Virol. 72
(1998) 4798–4810.
[39] S. Campbell, A. Rein, J. Virol. 73 (1999) 2270–2278.
[40] A. Deona, P. Spearman, L. Ratner, Virology 269 (2000) 305–312.
[41] M.I. Bukrinsky, S. Haggerty, M.P. Dempsey, N. Sharova, A.
Adzhubei, L. Spitz, P. Lewis, D. Goldfarb, M. Emerman, M. Steven-
son, Nature 365 (1993) 666–669.
[42] P. Gallay, S. Swingler, J. Song, F. Bushman, D. Trono, Cell 83
(1995) 569–576.
[43] A.G. Bukrinskaya, A. Ghorpade, N.K. Heinzinger, T.E. Smithgall,
R.E. Lewis, M. Stevenson, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
367–371.
[44] S. Dupont, N. Sharova, C. DeHoratius, C.-M. Virbasius, X. Zhu, A.
Burinskaya, M. Stevenson, M. Green, Nature 402 (1999) 681–685.
[45] J. Lanman, T.T. Lam, S. Barns, M. Sakalian, M.R. Emmett, A.G.
Marshall, P.E. Prevelige, J. Mol. Biol. 325 (2003) 759–772.
[46] W. Paxton, R.I. Conner, N.R. Landau, J. Virol. 67 (1993)
7229–7237.
S. Scarlata, C. Carter / Biochimica et Biophysica Acta 1614 (2003) 62–7272[47] P. Gamble, S. Yoo, F. Vajvos, U. von Schwedler, D. Worthphylake,
H. Wang, J. McCutcheon, W. Sundquist, C. Hill, Science 278 (1997)
849–853.
[48] S. Li, C. Hill, W. Sundquist, J. Finch, Nature 407 (2000) 409–413.
[49] C. Momany, L. Kovari, A. Prongay, W. Keller, R. Gitti, B. Lee, A.
Gorbalenya, L. Tong, J. McClure, L. Ehrlich, M. Summers, C. Carter,
M. Rossman, Nat. Struct. Biol. 3 (1996) 763–770.
[50] L. Dietrich, L. Ehrlich, T. LaGrassa, D. Ebbets-Reed, C. Carter,
J. Virol. 75 (2001) 4721–4733.
[51] S. Tang, T. Murakami, B. Agresta, S. Campbell, E.O. Freed, J.
Levin, J. Virol. 75 (2001) 9357–9366.
[52] R. Gitti, B. Lee, J. Walker, M.K. Summers, S. Yoo, W. Sundquist,
Science 273 (1996) 231–235.
[53] T. Gamble, S. Yoo, F. Vajdos, U. von Schwedler, D. Worthylake, H.
Wang, J. McCutcheon, W. Sundquist, C. Hill, Science 278 (1997)
849–853.
[54] C. Berthet-Colominas, S. Monaco, A. Novelli, G. Sibai, F. Mallet, S.
Cusak, EMBO J. 18 (1999) 1124–1136.
[55] C. Tang, Y. Ndassa, M.F. Summers, Nat. Struct. Biol. 9 (2002)
537–543.
[56] H.G. Krausslich, et al., J. Virol. 69 (1995) 3407–3415.
[57] L. Ehrlich, T. Liu, S. Scarlata, B. Chu, C. Carter, Biophys. J. 81
(2001) 586–594.
[58] I. Gross, H. Hohenberg, T. Wilk, K. Wiegers, M. Grattinger,
B. Muller, S.D. Fuller, H.G. Krausslich, EMBO J. 9 (2000)
103–113.
[59] J. Wills, R. Craven, AIDS 5 (1991) 639–654.
[60] F. Mammano, A. Ohagen, S. Hoglund, H. Gottlinger, J. Virol. 68
(1994) 4927–4936.
[61] N. Srinivasakanan, et al., J. Virol. 69 (1995) 6106–6612.
[62] D. Ebbets-Reed, S. Scarlata, C. Carter, Biochemistry 35 (1996)
14268–14275.
[63] P. Provitera, A. Goff, A. Harenberg, F. Bouamr, C. Carter, S. Scar-
lata, Biochemistry 40 (2001) 5565–5572.
[64] N.A. Kootsra, C. Monk, N. Tonnu, N.R. Landau, I. Verma, Proc.
Natl. Acad. Sci. U. S. A. 100 (2003) 1298–1303.
[65] G. Towers, M. Bock, S. Martin, Y. Teakeuchi, J. Stoye, O. Danos,
Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12295–12299.
[66] G. Towers, N. Collins, Y. Takeuchi, J. Virol. 76 (2002) 2548–2550.
[67] E.K. Franke, H.E. Yuan, J. Luban, Nature 372 (1994) 359–362.
[68] M. Thaili, A. Bukovsky, E. Kondo, B. Rosenwirth, C. Walsh, J.
Sodroski, H.G. Gottlinger, Nature 372 (1994) 363–365.
[69] R. Handschumacher, M.W. Harding, J. Rice, R.J. Drugge, Science
226 (1984) 544–547.
[70] D. Braaten, H. Ansari, J. Luban, J. Virol. 71 (1997) 2107–2113.
[71] D. Bosco, E. Eisenmesser, S. Pochapsky, W. Sundquist, D. Kern,
Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5247–5252.
[72] M. Endrich, P. Gehrig, H. Gehring, J. Biol. Chem. 274 (1999)
5326–5332 (274).
[73] D. Braaten, E. Franke, J. Luban, J. Virol. 70 (1996) 3551–3560.
[74] M. BonHomme, S. Wong, C. Carter, S. Scarlata, Biophys. Chem.
(2003) (in press).
[75] A. Saphire, M. Bobardt, P. Gallay, J. Virol. 76 (2002) 2255–2262.
[76] A. Saphire, M. Bobardt, P. Gallay, EMBO J. 18 (1999) 6771–6785.
[77] B. Sherry, G. Zybarth, M. Alfano, L. Dubrobsky, R. Mitchell, D.
Rich, P. Ulrich, R. Bucala, A. Cerami, M. Bukrinsky, Proc. Natl.
Acad. Sci. U. S. A. 95 (1998) 1758–1763.
[78] C. Cartier, P. Sivard, C. Tranchatt, D. Decimo, C. Desgranges, V.
Boyer, J. Biol. Chem. 274 (1999) 19434–19440.[79] C. Cartier, M. Deckert, C. Grangeasse, R. Trauger, F. Jensen, A.
Bernard, A. Cozzane, C. Desgranges, V. Boyer, J. Virol. 71 (1997)
4832–4837.
[80] G.K. Amarasinghe, J. Zhou, M. Miskimon, K.J. Chancellor, J.A.
McDonald, A.G. Matthews, R.R. Miller, M.D. Rouse, M.K.
Summers, J. Mol. Biol. 314 (2001) 961–970.
[81] A. Khorchid, R. Halwani, M.A. Wainberg, L. Kleiman, J. Virol. 76
(2002) 4131–4137.
[82] S.J. Kim, M.J. Kim, J.H. Lee, J.C. You, S. Jeong, Biochem. Bio-
phys. Res. Commun. 291 (2002) 925–931.
[83] W. Fu, et al., J. Virol. 68 (1994) 5013.
[84] Y.-X. Feng, et al., Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 7577.
[85] D. Muriaux, et al., J. Biol. Chem. 271 (1996) 33686.
[86] L. Parent, R. Bennett, R. Craven, T. Nelle, N. Krishna, J. Bowzard,
C. Wilson, B. Puffer, R. Montelaro, J. Wills, J. Virol. 69 (1995)
5455–5460.
[87] L. Garnier, B. Bowzard, J.W. Will, AIDS 12 (1998) S5–S16.
[88] A. Cimarelli, S. Sandin, S. Hoglund, J. Luban, J. Virol. 74 (2000)
4273–4283.
[89] S. Campbell, R. Fisher, E. Towler, A. Fox, H. Isaaq, T. Wolfe,
L. Phillips, A. Rein, Proc. Natl. Acad. Sci. U. S. A. 98 (2001)
10875–10879.
[90] Y.L. Lu, et al., J. Virol. 69 (1995) 6873–6879.
[91] E. Kondo, H.G. Gottlinger, J. Virol. 70 (1996) 1959–1964.
[92] N. Heinzinger, M. Bukinsky, S. Haggerty, A. Ragland, V. Kewal-
rammi, M.-A. Lee, H. Gendelman, L. Ratner, M. Stevenson, M.
Emerman, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7311–7315.
[93] H. deRocquigny, P. Petitjean, V. Tanchou, D. Decimo, L. Drouot,
T. Delaunay, J.-L. Darlix, B. Roques, J. Biol. Chem. 272 (1997)
30753–30759.
[94] H.G. Gottlinger, T. Dorfman, J. Sodroski, W. Haseltine, Proc. Natl.
Acad. Sci. U. S. A. 88 (1991) 3195–3199.
[95] L. VerPlank, F. Bouamr, A. LaGrassa, B.A. Kikonyogo, J. Leis, C.
Carter, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7724–7729.
[96] J.E. Garrus, et al., Cell 107 (2001) 55–65.
[97] J. Martin-Serrano, et al., Nat. Med. 7 (2001) 1313–1319.
[98] J. Martin-Serrano, T. Zang, P.D. Bieniasz, J. Virol. 77 (2003)
4794–4804.
[99] S. Lemmon, L. Traub, Curr. Opin. Cell Biol. 12 (2000) 457–466.
[100] J. Gruenberg, Nat. Rev., Mol. Biol. 2 (2001) 721–730.
[101] B. Strack, A. Calistri, M.A. Accola, G. Palu, H.G. Gottlinger, Proc.
Natl. Acad. Sci. U. S. A. 97 (2000) 13063–13068.
[102] B. Strack, A. Calistri, H.G. Gottlinger, J. Virol. 76 (2002)
5472–5479.
[103] J. Thrower, L. Hoffman, M. Reschsteiner, C. Pickart, EMBO J. 19
(2000) 94–102.
[104] E.O. Freed, Trends Microbiol. 11 (2003) 56–59.
[105] O. Pronillos, J.E. Garrus, W. Sundquist, Trends Cell Biol. 12 (2002)
569–579.
[106] C. Carter, Trends Microbiol. 10 (2002) 203–205.
[107] E.O. Freed, J. Virol. 76 (2002) 4679–4687.
[108] A. Ono, D. Demirov, E.O. Freed, J. Virol. 74 (2000) 5142–5150.
[109] A. Aldorini, R. Young, J. Virol. 64 (1990) 1920–1926.
[110] S.-F. Lee, C.-T. Wnag, J. Liang, S.-L. Hong, C.-C. Huang, S.S.-L.
Chen, J. Biol. Chem. 275 (2000) 15809–15819.
[111] M. Tritel, M. Resh, J. Virol. 74 (2001) 5473–5481.
